Erik Klapproth

Erik Klapproth

Auto-generated profile, based on publicly available information

Erik Klapproth

Institute of Pharmacology and Toxicology, Faculty of Medicine Carl Gustav Carus Technische Universität Dresden Dresden Germany

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 December 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
EKErik Klapproth
Erik Klapproth
AWAnke Witt
Anke Witt
PKPauline Klose
Pauline Klose
JWJohanna Wiedemann
Johanna Wiedemann
NVNikitha Vavilthota
Nikitha Vavilthota
AEAli El-Armouche
Ali El-Armouche
After myocardial infarction the innate immune response is pivotal in clearing of tissue debris as well as scar formation, but exaggerated cytokine and chemokine secretion with subsequent leukocyte infiltration also leads to further tissue damage. Here, we address the value of targeting a previously unknown a disintegrin and metalloprotease 10 (ADAM10)/CX3CL1 axis in the regulation of neutrophil recruitment early after MI. We show that myocardial ADAM10 is distinctly upregulated in myocardial biopsies from patients with ischemia-driven cardiomyopathy. Intriguingly, upon MI in mice, pharmacological ADAM10 inhibition as well as genetic cardiomycyte-specific ADAM10 deletion improves survival with markedly enhanced heart function and reduced scar size. Mechanistically, abolished ADAM10-mediated CX3CL1 ectodomain shedding leads to diminished IL-1β-dependent inflammation, reduced neutrophil bone marrow egress as well as myocardial tissue infiltration. Thus, our data shows a conceptual insight into how acute MI induces chemotactic signaling via ectodomain shedding in cardiomyocytes.

8 October 2025 in British Journal of Pharmacology
Verified
Journal Article
Open access
EKErik Klapproth
Erik Klapproth
JMJohanna Marks
Johanna Marks
Patrick Diaba-NuhohoPatrick Diaba-Nuhoho
Patrick Diaba-Nuhoho
SGSören Grell
Sören Grell
PLPaul Leubauer
Paul Leubauer
AEAli El‐Armouche
Ali El‐Armouche
Background and Purpose: Inflammation plays a crucial role in the development and progression of numerous acute and chronic diseases such as myocardial infarction (MI) and heart failure. Targeting ADAM proteases, particularly ADAM10, holds promise for fine‐tuning inflammatory responses. However, developing selective inhibitors has proven challenging because of cross‐inhibition of other metalloproteases. Protein‐based inhibitors, such as the synthetic ADAM10 prodomain, offer potential for improved selectivity and effectiveness. Experimental Approach: A novel ADAM10 inhibitor, VTH144, was designed by modifying the ADAM10 prodomain and evaluated empirically for selectivity, efficacy and toxicity both in vitro and in vivo and by using machine learning–based modelling. Key Results: AlphaFold3 predictions confirm that the ADAM10 prodomain is highly selective for its protease and identify VTH144 as a unique ADAM10‐inhibiting peptide. Fluorescence resonance energy transfer (FRET) assays verified VTH144 as highly selective for ADAM10, sparing other metalloproteases. In a MI mouse model, we show that VTH144 applied twice, 4 and 48 h after ligation of the left ventricular descending artery (LAD), is highly effective in preserving cardiac function by reducing scar size. VTH144 significantly attenuates ADAM10‐mediated CX 3 CL1 shedding, subsequent neutrophil infiltration into the heart and IL‐1β‐driven systemic inflammation. Importantly, safety pharmacology in naïve mice revealed that ADAM10 inhibition with VTH144 lacks toxic short‐term effects in cardiac, pulmonary, hepatic or renal systems. Conclusions and Implications: Our study highlights the potential of the selective ADAM10 inhibitor VTH144 as a promising therapeutic candidate for improving cardiac function and reducing the risk of heart failure following myocardial infarction.